{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:58:35Z","timestamp":1785542315293,"version":"3.56.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40268-018-0246-8","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T14:47:26Z","timestamp":1535726846000},"page":"167-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Critical Review of the Use of Second-Generation Antipsychotics in Obsessive\u2013Compulsive and Related Disorders"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-6823","authenticated-orcid":false,"given":"Dongmi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Ryba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kalabalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia","family":"Westrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"246_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders [Internet].","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders [Internet]. 5th ed. Washington, DC: American Psychiatric Association; 2013.","edition":"5"},{"key":"246_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/da.22259","volume":"31","author":"Ameringen M Van","year":"2014","unstructured":"Van Ameringen M, Patterson BN, Simpson W. DSM-5 Obsessive-compulsive and related disorders: clinical implications of new criteria. Depress Anxiety. 2014;31:487\u201393.","journal-title":"Depress Anxiety."},{"key":"246_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/13651501.2017.1291839","volume":"21","author":"A Hasan","year":"2017","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenth\u00f8j B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia \u2013 a short version for primary care. Int J Psychiatry Clin Pract. 2017;21:82\u201390.","journal-title":"Int J Psychiatry Clin Pract."},{"key":"246_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.janxdis.2016.08.003","volume":"43","author":"L-G \u00d6st","year":"2016","unstructured":"\u00d6st L-G, Riise EN, Wergeland GJ, Hansen B, Kvale G. Cognitive behavioral and pharmacological treatments of OCD in children: a systematic review and meta-analysis. J Anxiety Disord. 2016;43:58\u201369.","journal-title":"J Anxiety Disord"},{"key":"246_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/JCNSD.S38359","volume":"8","author":"AM Rapp","year":"2016","unstructured":"Rapp AM, Bergman RL, Piacentini J, McGuire JF. Evidence-based assessment of obsessive-compulsive disorder. J Cent Nerv Syst Dis. 2016;8:13\u201329 (Internet Libertas Academica).","journal-title":"J Cent Nerv Syst Dis."},{"key":"246_CR6","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.2147\/NDT.S67636","volume":"11","author":"\u00c1 Fr\u00edas","year":"2015","unstructured":"Fr\u00edas \u00c1, Palma C, Farriols N, Gonz\u00e1lez L. Comorbidity between obsessive-compulsive disorder and body dysmorphic disorder: prevalence, explanatory theories, and clinical characterization. Neuropsychiatr Dis Treat. 2015;11:2233\u201344.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"246_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0272-7358(00)00075-1","volume":"21","author":"MB Cororve","year":"2001","unstructured":"Cororve MB, Gleaves DH. Body dysmorphic disorder: a review of conceptualizations, assessment, and treatment strategies. Clin Psychol Rev. 2001;21:949\u201370.","journal-title":"Clin Psychol Rev."},{"key":"246_CR8","first-page":"17","volume":"33","author":"KA Phillips","year":"1997","unstructured":"Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997;33:17\u201322.","journal-title":"Psychopharmacol Bull"},{"key":"246_CR9","first-page":"415","volume":"52","author":"GA Christenson","year":"1991","unstructured":"Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry. 1991;52:415\u20137.","journal-title":"J Clin Psychiatry"},{"key":"246_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2016.15111432","volume":"173","author":"JE Grant","year":"2016","unstructured":"Grant JE, Chamberlain SR. Trichotillomania. Am J Psychiatry. 2016;173:868\u201374.","journal-title":"Am J Psychiatry"},{"key":"246_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000289003","volume":"64","author":"NJ Keuthen","year":"1995","unstructured":"Keuthen NJ, O\u2019Sullivan RL, Ricciardi JN, Shera D, Savage CR, Borgmann AS, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. Development and factor analyses. Psychother Psychosom. 1995;64:141\u20135.","journal-title":"Psychother Psychosom"},{"key":"246_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.genhosppsych.2016.04.001","volume":"41","author":"RR Selles","year":"2016","unstructured":"Selles RR, McGuire JF, Small BJ, Storch EA. A systematic review and meta-analysis of psychiatric treatments for excoriation (skin-picking) disorder. Gen Hosp Psychiatry. 2016;41:29\u201337.","journal-title":"Gen Hosp Psychiatry"},{"key":"246_CR13","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMcp1313051","volume":"370","author":"D Mataix-Cols","year":"2014","unstructured":"Mataix-Cols D. Hoarding disorder. N Engl J Med. 2014;370:2023\u201330.","journal-title":"N Engl J Med"},{"key":"246_CR14","volume-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","author":"American Psychiatric Association","year":"2007","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association; 2007. http:\/\/www.psych.org\/psych_pract\/treatg\/pg\/prac_guide.cfm ."},{"key":"246_CR15","unstructured":"The British Psychological Society. Obsessive- compulsive disorder: Core interventions in the treatment of obsessive- compulsive disorder and body dysmorphic disorder British Library Cataloguing-in-Publication Data. Br Psychol Soc R Coll Psychiatr. 2006."},{"key":"246_CR16","doi-asserted-by":"publisher","unstructured":"Rothbart R, Amos T, Siegfried N, Ipser JC, Fineberg N, Chamberlain SR, et al. Pharmacotherapy for trichotillomania. In: Stein DJ, editor. Cochrane Database Syst Rev. 2013; https:\/\/doi.org\/10.1002\/14651858.cd007662.pub2","DOI":"10.1002\/14651858.cd007662.pub2"},{"key":"246_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2009.08.043","volume":"289","author":"OA Heuvel Van den","year":"2010","unstructured":"Van den Heuvel OA, van den Werf YD, van Verhoef KMW, de Wit S, Berendse HW, Wolters EC, et al. Frontal\u2013striatal abnormalities underlying behaviours in the compulsive\u2013impulsive spectrum. J Neurol Sci. 2010;289:55\u20139.","journal-title":"J Neurol Sci."},{"key":"246_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.euroneuro.2015.12.005","volume":"26","author":"OA Heuvel van den","year":"2016","unstructured":"van den Heuvel OA, van Wingen G, Soriano-Mas C, Alonso P, Chamberlain SR, Nakamae T, et al. Brain circuitry of compulsivity. Eur Neuropsychopharmacol. 2016;26:810\u201327.","journal-title":"Eur Neuropsychopharmacol"},{"key":"246_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pbj.2016.07.005","volume":"1","author":"\u00d3F Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves \u00d3F, Carvalho S, Leite J, Fernandes-Gon\u00e7alves A, Carracedo A, Sampaio A. Cognitive and emotional impairments in obsessive\u2013compulsive disorder: evidence from functional brain alterations. Porto Biomed J. 2016;1:92\u2013105.","journal-title":"Porto Biomed J."},{"key":"246_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0006-3223(03)00168-9","volume":"54","author":"ML Phillips","year":"2003","unstructured":"Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry. 2003;54:504\u201314.","journal-title":"Biol Psychiatry."},{"key":"246_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0006-3223(03)00171-9","volume":"54","author":"ML Phillips","year":"2003","unstructured":"Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry. 2003;54:515\u201328.","journal-title":"Biol Psychiatry."},{"key":"246_CR22","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.euroneuro.2015.12.033","volume":"26","author":"CM Gillan","year":"2016","unstructured":"Gillan CM, Robbins TW, Sahakian BJ, van den Heuvel OA, van Wingen G. The role of habit in compulsivity. Eur Neuropsychopharmacol. 2016;26:828\u201340.","journal-title":"Eur Neuropsychopharmacol"},{"key":"246_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bodyim.2007.11.002","volume":"5","author":"JD Feusner","year":"2008","unstructured":"Feusner JD, Yaryura-Tobias J, Saxena S. The pathophysiology of body dysmorphic disorder. Body Image.\u00a02008;5:3\u201312.","journal-title":"Body Image."},{"key":"246_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pscychresns.2017.09.006","volume":"269","author":"MD Harries","year":"2017","unstructured":"Harries MD, Chamberlain SR, Redden SA, Odlaug BL, Blum AW, Grant JE. A structural MRI study of excoriation (skin-picking) disorder and its relationship to clinical severity. Psychiatry Res Neuroimaging. 2017;269:26\u201330.","journal-title":"Psychiatry Res Neuroimaging."},{"issue":"3","key":"246_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1026\/1616-3443\/a000213","volume":"42","author":"W Li","year":"2013","unstructured":"Li W, Arienzo D, Feusner JD. Body Dysmorphic disorder: neurobiological features and an updated model. Z Klin Psycho Psychother (Gott). 2013;42(3):184\u201391.","journal-title":"Z Klin Psycho Psychother (Gott)."},{"key":"246_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0006-3223(99)00271-1","volume":"47","author":"DJ Stein","year":"2000","unstructured":"Stein DJ. Neurobiology of the obsessive\u2013compulsive spectrum disorders. Biol Psychiatry. 2000;47:296\u2013304.","journal-title":"Biol Psychiatry"},{"key":"246_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jad.2009.08.012","volume":"123","author":"M Atmaca","year":"2010","unstructured":"Atmaca M, Bingol I, Aydin A, Yildirim H, Okur I, Yildirim MA, et al. Brain morphology of patients with body dysmorphic disorder. J Affect Disord. 2010;123:258\u201363.","journal-title":"J Affect Disord"},{"key":"246_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1192\/bjp.bp.114.155192","volume":"208","author":"BL Odlaug","year":"2016","unstructured":"Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain activation in excoriation (skin-picking) disorder: evidence from an executive planning fMRI study. Br J Psychiatry. 2016;208:168\u201374.","journal-title":"Br J Psychiatry"},{"key":"246_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/pcn.12242","volume":"69","author":"I Kusumi","year":"2005","unstructured":"Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2005;69:243\u201358.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"246_CR30","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400\u201311.","journal-title":"Neuropsychopharmacology."},{"key":"246_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I. In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"246_CR32","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400\u201311.","journal-title":"Neuropsychopharmacology."},{"key":"246_CR33","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","volume":"33","author":"NH Jensen","year":"2008","unstructured":"Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT 1A agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacology. 2008;33:2303\u201312.","journal-title":"Neuropsychopharmacology."},{"key":"246_CR34","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cmdc.200800074","volume":"2","author":"J Selent","year":"2008","unstructured":"Selent J, L\u00f3pez L, Sanz F, Pastor M. Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new b 2 adrenergic receptor template. ChemMedChem. 2008;2:1194\u20138.","journal-title":"ChemMedChem"},{"key":"246_CR35","first-page":"47","volume":"55 Suppl B","author":"HY Meltzer","year":"1994","unstructured":"Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55 Suppl B:47\u201352.","journal-title":"J Clin Psychiatry."},{"key":"246_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/YIC.0b013e32832e9b91","volume":"24","author":"E Pessina","year":"2009","unstructured":"Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive\u2013compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24:265\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"246_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12325-011-0011-7","volume":"28","author":"M Ak","year":"2011","unstructured":"Ak M, Bulut SD, Bozkurt A, Ozsahin A. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Ther. 2011;28:341\u20138.","journal-title":"Adv Ther."},{"key":"246_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","volume":"31","author":"MRA Muscatello","year":"2011","unstructured":"Muscatello MRA, Bruno A, Pandolfo G, Mic\u00f2 U, Scimeca G, Romeo VM, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31:174\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/da.21996","volume":"29","author":"M Sayyah","year":"2012","unstructured":"Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. 2012;29:850\u20134.","journal-title":"Depress Anxiety."},{"key":"246_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/1745017901107010107","volume":"7","author":"R Delle Chiaie","year":"2011","unstructured":"Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health. 2011;7:107\u201311.","journal-title":"Clin Pract Epidemiol Ment Health."},{"key":"246_CR41","doi-asserted-by":"publisher","first-page":"S533","DOI":"10.1016\/S0924-977X(13)70847-2","volume":"82","author":"C Segalas","year":"2013","unstructured":"Segalas C, Alonso P, Real E, Lopez-Sola C, Estevez M, Menchon J. Aripiprazole in obsessive-compulsive disorder: A case series of 71 patients refractory to other antipsychotics augmentation strategies. Eur Neuropsychopharmacol. 2013;82:S533\u20134.","journal-title":"Eur Neuropsychopharmacol."},{"key":"246_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4088\/JCP.v66n0107","volume":"66","author":"KM Connor","year":"2005","unstructured":"Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JRT. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66:49\u201351.","journal-title":"J Clin Psychiatry"},{"key":"246_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hup.1169","volume":"26","author":"Y Selvi","year":"2011","unstructured":"Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol Clin Exp. 2011;26:51\u20137.","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"246_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/2045125314560739","volume":"5","author":"S Shoja Shafti","year":"2015","unstructured":"Shoja Shafti S, Kaviani H. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial. Ther Adv Psychopharmacol. 2015;5:32\u20137.","journal-title":"Ther Adv Psychopharmacol."},{"key":"246_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/13651501.2011.605958","volume":"15","author":"H Matsunaga","year":"2011","unstructured":"Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract. 2011;15:263\u20139.","journal-title":"Int J Psychiatry Clin Pract."},{"key":"246_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/13651501.2016.1225098","volume":"21","author":"A Hegde","year":"2017","unstructured":"Hegde A, Kalyani BG, Arumugham SS, Narayanaswamy JC, Math SB, Reddy YCJ. Aripiprazole augmentation in highly treatment-resistant obsessive\u2013compulsive disorder\u2014experience from a specialty clinic in India. Int J Psychiatry Clin Pract. 2017;21:67\u20139.","journal-title":"Int J Psychiatry Clin Pract."},{"key":"246_CR47","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0004867416656262","volume":"50","author":"S Patra","year":"2016","unstructured":"Patra S. Treat the disease not the symptoms: successful management of obsessive compulsive disorder in bipolar disorder with aripiprazole augmentation. Aust N Zeal J Psychiatry. 2016;50:809\u201310.","journal-title":"Aust N Zeal J Psychiatry."},{"key":"246_CR48","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1176\/appi.neuropsych.13050103","volume":"26","author":"Y-C Hou","year":"2014","unstructured":"Hou Y-C, Lai C-H. Rapid responses of high-dose combined therapy of escitalopram and aripiprazole in a case of severe obsessive compulsive disorder with delusion. J Neuropsychiatry Clin Neurosci. 2014;26:E44\u20135.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"246_CR49","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.pnpbp.2007.07.008","volume":"31","author":"FF Rocha da","year":"2007","unstructured":"da Rocha FF, Correa H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive\u2013compulsive disorder. Prog Neuro-Psychopharmacology Biol Psychiatry. 2007;31:1550\u20131.","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"246_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/10401230701465277","volume":"19","author":"AR Curtis","year":"2007","unstructured":"Curtis AR, Richards RW. The Treatment of Psychogenic Excoriation and Obsessive Compulsive Disorder Using Aripiprazole and Fluoxetine. Ann Clin Psychiatry. 2007;19:199\u2013200.","journal-title":"Ann Clin Psychiatry"},{"key":"246_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5350\/DAJPN2016290209","volume":"32","author":"F Izci","year":"2016","unstructured":"Izci F, Yalcin M, Kurtulus Calli SY, Sever Y, Bilici R. Aripiprazole augmentation of clomipramine therapy in treatment-resistant obsessive-compulsive disorder: case series. Dusunen Adam J Psychiatry Neurol Sci. 2016;32:167\u201372.","journal-title":"Dusunen Adam J Psychiatry Neurol Sci."},{"key":"246_CR52","first-page":"19","volume":"14","author":"DL Ginsberg","year":"2007","unstructured":"Ginsberg DL. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. Prim Psychiatry. 2007;14:19\u201320.","journal-title":"Prim Psychiatry."},{"key":"246_CR53","doi-asserted-by":"publisher","first-page":"E64","DOI":"10.1176\/appi.neuropsych.13100245","volume":"26","author":"M Takaki","year":"2014","unstructured":"Takaki M. Aripiprazole as monotherapy at bedtime was effective for treatment of two cases of obsessive-compulsive disorder and insomnia. J Neuropsychiatry Clin Neurosci. 2014;26:E64.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"246_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3109\/15622975.2010.551667","volume":"13","author":"H Higuma","year":"2012","unstructured":"Higuma H, Kanehisa M, Maruyama Y, Ishitobi Y, Tanaka Y, Tsuru J, et al. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. World J Biol Psychiatry. 2012;13:14\u201321.","journal-title":"World J Biol Psychiatry."},{"key":"246_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/NDT.S122316","volume":"13","author":"J Lai","year":"2017","unstructured":"Lai J, Lu Q, Zhang P, Xu T, Xu Y, Hu S. Aripiprazole augmentation in managing comorbid obsessive-compulsive disorder and bipolar disorder: a case with suicidal attempts. Neuropsychiatr Dis Treat. 2017;13:87\u201390.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"246_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859x-7-26","author":"M Fornaro","year":"2008","unstructured":"Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann Gen Psychiatry. 2008. https:\/\/doi.org\/10.1186\/1744-859x-7-26 .","journal-title":"Ann Gen Psychiatry."},{"key":"246_CR57","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00213-008-1091-1","volume":"197","author":"R Sarkar","year":"2008","unstructured":"Sarkar R, Klein J, Kr\u00fcger S. Aripiprazole augmentation in treatment-refractory obsessive\u2013compulsive disorder. Psychopharmacology. 2008;197:687\u20138.","journal-title":"Psychopharmacology"},{"key":"246_CR58","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4088\/JCP.v68n0624d","volume":"68","author":"S Friedman","year":"2007","unstructured":"Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi J-D. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2007;68:972\u20133.","journal-title":"J Clin Psychiatry"},{"key":"246_CR59","first-page":"18","volume":"2","author":"AK Ashton","year":"2005","unstructured":"Ashton AK. Aripiprazole augmentation of combination escitalopram and sertraline in the treatment of refractory obsessive-compulsive disorder. Psychiatry (Edgmont). 2005;2:18.","journal-title":"Psychiatry (Edgmont)."},{"key":"246_CR60","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.genhosppsych.2010.07.004","volume":"32","author":"F Uguz","year":"2010","unstructured":"Uguz F. Successful treatment of comorbid obsessive\u2013compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry. 2010;32:556\u20138.","journal-title":"Gen Hosp Psychiatry"},{"key":"246_CR61","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1440-1819.2009.01938.x","volume":"63","author":"C-U Pae","year":"2009","unstructured":"Pae C-U. Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2009;63:593.","journal-title":"Psychiatry Clin Neurosci"},{"key":"246_CR62","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/JCP.0b013e31817d86cc","volume":"28","author":"C Winter","year":"2008","unstructured":"Winter C, Heinz A, Kupsch A, Str\u00f6hle A. Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder. J Clin Psychopharmacol. 2008;28:452\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR63","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1176\/ajp.152.12.1812","volume":"152","author":"CJ McDougle","year":"1995","unstructured":"McDougle CJ, Barr LC, Goodman W, Pelton GH, Al E. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1812\u20134.","journal-title":"Am J Psychiatry"},{"key":"246_CR64","first-page":"209","volume":"14","author":"C Young","year":"1994","unstructured":"Young C, Bostic J, McDanald C. Clozapine and refractory obsessive-compulsive disorder: a Case Report. J Clin Psychiatry. 1994;14:209\u201310.","journal-title":"J Clin Psychiatry"},{"key":"246_CR65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-2007-979555","volume":"29","author":"T Steinert","year":"1996","unstructured":"Steinert T, Schmidt-Michel WWPK. Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Pharmacopsychiatry. 1996;29:111\u20134.","journal-title":"Pharmacopsychiatry."},{"key":"246_CR66","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","volume":"55","author":"NA Shapira","year":"2004","unstructured":"Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MCK, Blier P, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55:553\u20135.","journal-title":"Biol Psychiatry"},{"key":"246_CR67","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","volume":"18","author":"G Maina","year":"2008","unstructured":"Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18:364\u201372.","journal-title":"Eur Neuropsychopharmacol"},{"key":"246_CR68","doi-asserted-by":"publisher","first-page":"863","DOI":"10.4088\/JCP.08m04369","volume":"70","author":"H Matsunaga","year":"2009","unstructured":"Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009;70:863\u20138.","journal-title":"J Clin Psychiatry"},{"key":"246_CR69","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/070674370104600408","volume":"46","author":"G Francobandiera","year":"2001","unstructured":"Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry. 2001;46:356\u20138.","journal-title":"Can J Psychiatry"},{"key":"246_CR70","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/0269881105053299","volume":"19","author":"D Marazziti","year":"2005","unstructured":"Marazziti D, Pfanner C, Dell\u2019Osso B, Ciapparelli A, Presta S, Corretti G, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol. 2005;19:392\u20134.","journal-title":"J Psychopharmacol."},{"key":"246_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0165-1781(00)00203-1","volume":"96","author":"F Bogetto","year":"2000","unstructured":"Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000;96:91\u20138.","journal-title":"Psychiatry Res"},{"key":"246_CR72","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4088\/JCP.v61n0709","volume":"61","author":"L Koran","year":"2000","unstructured":"Koran L, Ringold A, Elliott M. Olanzapine augmentation for treatment-resistant obsessive compulsive disorder. J Clin Psychiatry. 2000;61:514\u20137.","journal-title":"J Clin Psychiatry"},{"key":"246_CR73","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0924-9338(02)00673-9","volume":"17","author":"MA Crocq","year":"2002","unstructured":"Crocq MA, Leclercq P, Guillon MS, Bailey PE. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment [1]. Eur Psychiatry. 2002;17:296\u20137.","journal-title":"Eur Psychiatry"},{"key":"246_CR74","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0278-5846(03)00050-2","volume":"27","author":"G D\u2019Amico","year":"2003","unstructured":"D\u2019Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuro-Psychopharmacology Biol Psychiatry. 2003;27:619\u201323.","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"246_CR75","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4088\/JCP.v64n0518c","volume":"64","author":"M Poyurovsky","year":"2003","unstructured":"Poyurovsky M, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64:611.","journal-title":"J Clin Psychiatry"},{"key":"246_CR76","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/00004714-199810000-00014","volume":"18","author":"MN Potenza","year":"1998","unstructured":"Potenza MN, Wasylink S, Longhurst J, Neill Epperson C, McDougle CJ. Olanzapine Augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 1998;18:423\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR77","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/070674370404900812","volume":"49","author":"P Petrikis","year":"2004","unstructured":"Petrikis P, Andreou C, Bozikas V, Karavatos A. Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder. Can J Psychiatry. 2004;49:572\u20133.","journal-title":"Can J Psychiatry."},{"key":"246_CR78","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1176\/ajp.156.11.1834-a","volume":"156","author":"D Marazziti","year":"1999","unstructured":"Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry. 1999;156:1834\u20135.","journal-title":"Am J Psychiatry"},{"key":"246_CR79","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1176\/ajp.155.6.855","volume":"155","author":"D Morrison","year":"1998","unstructured":"Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry. 1998;155:855.","journal-title":"Am J Psychiatry"},{"key":"246_CR80","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-2000-8360","volume":"33","author":"R Ramasubbu","year":"2000","unstructured":"Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry. 2000;33:236\u20138.","journal-title":"Pharmacopsychiatry."},{"key":"246_CR81","first-page":"393","volume":"45","author":"D Degner","year":"2000","unstructured":"Degner D, Bleich S, Kornhuber J, Ruther E. Olanzapine treatment of obsessive-compulsive disorder. Can J Psychiatry. 2000;45:393.","journal-title":"Can J Psychiatry"},{"key":"246_CR82","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1192\/bjp.177.6.567-a","volume":"177","author":"A Marusic","year":"2000","unstructured":"Marusic A, Farmer A. Antidepressant augmentation with low-dose olanzapine in obsessive\u2014compulsive disorder. Br J Psychiatry. 2000;177:567.","journal-title":"Br J Psychiatry"},{"key":"246_CR83","doi-asserted-by":"publisher","first-page":"524","DOI":"10.4088\/JCP.v60n0804","volume":"60","author":"E Weiss","year":"1999","unstructured":"Weiss E, Potenza MN, McDougle CJ, Neill Epperson C. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999;60:524\u20137.","journal-title":"J Clin Psychiatry"},{"key":"246_CR84","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.4088\/JCP.12m08278","volume":"74","author":"EA Storch","year":"2013","unstructured":"Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, et al. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013;74:e527\u201332.","journal-title":"J Clin Psychiatry."},{"key":"246_CR85","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/JCP.0b013e3182367aee","volume":"31","author":"JB Diniz","year":"2011","unstructured":"Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011;31:763\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR86","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","volume":"28","author":"A Kordon","year":"2008","unstructured":"Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2008;28:550\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR87","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-244X-5-5","volume":"5","author":"PD Carey","year":"2005","unstructured":"Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005;5:5.","journal-title":"BMC Psychiatry."},{"key":"246_CR88","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","volume":"20","author":"NA Fineberg","year":"2005","unstructured":"Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005;20:223\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"246_CR89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4088\/JCP.v66n0110","volume":"66","author":"AM Bogan","year":"2005","unstructured":"Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry. 2005;66:73\u20139.","journal-title":"J Clin Psychiatry"},{"key":"246_CR90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/00004850-200205000-00004","volume":"17","author":"M Atmaca","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"246_CR91","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","volume":"65","author":"D Denys","year":"2004","unstructured":"Denys D, de Geus F, van Megen H, Westenberg HGM. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1040\u20138.","journal-title":"J Clin Psychiatry"},{"key":"246_CR92","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4088\/JCP.08m04269","volume":"70","author":"NCC Vulink","year":"2009","unstructured":"Vulink NCC, Denys D, Fluitman SBAHA, Meinardi JCM, Westenberg HGM. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70:1001\u20138.","journal-title":"J Clin Psychiatry"},{"key":"246_CR93","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00044011-200828070-00005","volume":"28","author":"HA Savas","year":"2008","unstructured":"Savas HA, Yumru M, Ozen ME. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig. 2008;28:439\u201342.","journal-title":"Clin Drug Investig."},{"key":"246_CR94","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.4088\/JCP.v63n1116d","volume":"63","author":"G Francobandiera","year":"2002","unstructured":"Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J Clin Psychiatry. 2002;63:1046\u20137.","journal-title":"J Clin Psychiatry"},{"key":"246_CR95","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1017\/S1092852900015029","volume":"11","author":"B Dell\u2019Osso","year":"2006","unstructured":"Dell\u2019Osso B, Mundo E, Altamura AC. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. CNS Spectr. 2006;11:879\u201383 (quiz 885).","journal-title":"CNS Spectr."},{"key":"246_CR96","first-page":"17","volume":"2","author":"M Menaster","year":"2005","unstructured":"Menaster M. Efficacy of quetiapine in panic disorder with agoraphobia and obsessive-compulsive disorder in a patient with bipolar disorder. Psychiatry (Edgmont). 2005;2:17\u20138.","journal-title":"Psychiatry (Edgmont)"},{"key":"246_CR97","doi-asserted-by":"crossref","unstructured":"Foa EB, Simpson HB, Rosenfield D, Liebowitz MR, Cahill SP, Huppert JD, et al. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. J Clin Psychiatry. 2015;440\u20136.","DOI":"10.4088\/JCP.14m09044"},{"key":"246_CR98","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","volume":"70","author":"HB Simpson","year":"2013","unstructured":"Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder. JAMA Psychiatry. 2013;70:1190 (American Medical Association).","journal-title":"JAMA Psychiatry."},{"key":"246_CR99","first-page":"926","volume":"83","author":"MG Wheaton","year":"2015","unstructured":"Wheaton MG, Rosenfield D, Foa EB, Simpson HB. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: what moderates improvement? J Consult Clin Psychol. NIH Public Access. 2015;83:926\u201337.","journal-title":"NIH Public Access"},{"key":"246_CR100","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/JCP.0000000000000515","volume":"36","author":"A Hegde","year":"2016","unstructured":"Hegde A, Kalyani BG, Arumugham SS, Narayanaswamy JC, Math SB, Reddy YCJ. Effectiveness of risperidone augmentation in obsessive-compulsive disorder. J Clin Psychopharmacol. 2016;36:381\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR101","doi-asserted-by":"publisher","first-page":"S14611457030037","DOI":"10.1017\/S1461145703003730","volume":"6","author":"E Hollander","year":"2003","unstructured":"Hollander E, Rossi NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive\u2013compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6:S1461145703003730.","journal-title":"Int J Neuropsychopharmacol"},{"key":"246_CR102","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LHJHG, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794.","journal-title":"Arch Gen Psychiatry"},{"key":"246_CR103","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","volume":"15","author":"S Erzegovesi","year":"2005","unstructured":"Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15:69\u201374.","journal-title":"Eur Neuropsychopharmacol"},{"key":"246_CR104","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0924-977X(00)80450-2","volume":"10","author":"C Pfanner","year":"2000","unstructured":"Pfanner C, Marazziti D, Dell\u2019Osso L, Presta S, Gemignani A, Milanfranchi A, et al. Risperidone augmentation in refractory obsessive compulsive disorder: an open-label study. Eur Neuropsychopharmacol. 2000;10:349\u201350.","journal-title":"Eur Neuropsychopharmacol"},{"key":"246_CR105","first-page":"303","volume":"57","author":"S Saxena","year":"1996","unstructured":"Saxena S, Wang D, Bystritsky A, Baxter L. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996;57:303\u20136 (Physicians Postgraduate Press).","journal-title":"J Clin Psychiatry."},{"key":"246_CR106","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4088\/JCP.v66n0610","volume":"66","author":"X Li","year":"2005","unstructured":"Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder : a crossover study. J Clin Psychiatry. 2005;66:736\u201343.","journal-title":"J Clin Psychiatry"},{"key":"246_CR107","first-page":"526","volume":"56","author":"CJ McDougle","year":"1995","unstructured":"McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1995;56:526\u20138.","journal-title":"J Clin Psychiatry"},{"key":"246_CR108","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1440-1819.2006.01519.x","volume":"60","author":"R Yoshimura","year":"2006","unstructured":"Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci. 2006;60:389\u201393.","journal-title":"Psychiatry Clin Neurosci"},{"key":"246_CR109","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1046\/j.1440-1819.2000.00760.x","volume":"54","author":"T Kawahara","year":"2000","unstructured":"Kawahara T, Ueda Y, Mitsuyama Y. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci. 2000;54:599\u2013601.","journal-title":"Psychiatry Clin Neurosci"},{"key":"246_CR110","first-page":"587","volume":"24","author":"T Sun","year":"2001","unstructured":"Sun T, Lin P, Wu C. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessivecompulsive disorder: report of two cases. Chang Gung Med J. 2001;24:587\u201392.","journal-title":"Chang Gung Med J."},{"key":"246_CR111","first-page":"677","volume":"32","author":"L Ravizza","year":"1996","unstructured":"Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 1996;32:677\u201382.","journal-title":"Psychopharmacol Bull"},{"key":"246_CR112","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4088\/JCP.v58n0306","volume":"58","author":"DJ Stein","year":"1997","unstructured":"Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997;58:119\u201322.","journal-title":"J Clin Psychiatry"},{"key":"246_CR113","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4088\/JCP.v60n0112d","volume":"60","author":"O Agid","year":"1999","unstructured":"Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry. 1999;60:55\u20136.","journal-title":"J Clin Psychiatry"},{"key":"246_CR114","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4088\/JCP.v59n0509c","volume":"59","author":"C Andrade","year":"1998","unstructured":"Andrade C. Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry. 1998;59:255\u20136.","journal-title":"J Clin Psychiatry"},{"key":"246_CR115","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/WNF.0000000000000123","volume":"39","author":"A Bruno","year":"2016","unstructured":"Bruno A, Pandolfo G, Cedro C, Gallo G, De Felice M, Zoccali RA, et al. Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Clin Neuropharmacol. 2016;39:6\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"246_CR116","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sj.mp.4001823","volume":"11","author":"MH Bloch","year":"2006","unstructured":"Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622\u201332.","journal-title":"Mol Psychiatry."},{"key":"246_CR117","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","volume":"17","author":"P Skapinakis","year":"2007","unstructured":"Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17:79\u201393.","journal-title":"Eur Neuropsychopharmacol"},{"key":"246_CR118","doi-asserted-by":"publisher","unstructured":"Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. In: Komossa K, editor. Cochrane Database Syst Rev. 2010. https:\/\/doi.org\/10.1002\/14651858.cd008141.pub2 .","DOI":"10.1002\/14651858.cd008141.pub2"},{"key":"246_CR119","unstructured":"Maglione M, Ruelaz Maher A, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-label use of atypical antipsychotics: an update. Rockville, MD: Agency for Healthcare Research and Quality; 2011. http:\/\/www.effectivehealthcare.ahrq.gov\/reports\/final.cfm ."},{"key":"246_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv047","volume":"18","author":"M Dold","year":"2015","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive- compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18:1\u201311.","journal-title":"Int J Neuropsychopharmacol."},{"key":"246_CR121","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1017\/S1461145712000740","volume":"16","author":"M Dold","year":"2013","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16:557\u201374.","journal-title":"Int J Neuropsychopharmacol"},{"key":"246_CR122","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"AR Maher","year":"2011","unstructured":"Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. JAMA. 2011;306:1359\u201369.","journal-title":"JAMA"},{"key":"246_CR123","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","volume":"14","author":"D Veale","year":"2014","unstructured":"Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317.","journal-title":"BMC Psychiatry"},{"key":"246_CR124","doi-asserted-by":"crossref","unstructured":"National Collaborating Centre for Mental Health. Obsessive-compulsive disorder and body dysmorphic disorder: treatment. Natl Inst Heal Clin Excell. 2006. National Clinical Practice Guideline Number 31.","DOI":"10.7748\/mhp.9.6.31.s29"},{"key":"246_CR125","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/11536730-000000000-00000","volume":"30","author":"O Uzun","year":"2010","unstructured":"Uzun O, Ozdemir B. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clin Drug Investig. 2010;30:707\u201311.","journal-title":"Clin Drug Investig."},{"key":"246_CR126","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1176\/appi.ajp.162.5.1022-a","volume":"162","author":"KA Phillips","year":"2005","unstructured":"Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162:1022\u20133.","journal-title":"Am J Psychiatry"},{"key":"246_CR127","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1440-1819.2008.01813.x","volume":"62","author":"S Nakaaki","year":"2008","unstructured":"Nakaaki S, Murata Y, Furukawa TA. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci. 2008;62:370.","journal-title":"Psychiatry Clin Neurosci"},{"key":"246_CR128","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4088\/JCP.v62n0413e","volume":"62","author":"JE Grant","year":"2001","unstructured":"Grant JE. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry. 2001;62:297\u20138.","journal-title":"J Clin Psychiatry"},{"key":"246_CR129","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881113512042","volume":"28","author":"JB Diniz","year":"2014","unstructured":"Diniz JB, Costa DL, Cassab RC, Pereira CA, Miguel EC, Shavitt RG. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. J Psychopharmacol. 2014;28:603\u201311.","journal-title":"J Psychopharmacol."},{"key":"246_CR130","first-page":"286","volume":"15","author":"P Goulia","year":"2011","unstructured":"Goulia P, Mantas C, Bassukas ID, Hyphantis T. Treatment with risperidone and venlafaxine of a patient with double-coded diagnosis of body dysmorphic disorder and delusional disorder somatic type. Hippokratia. 2011;15:286\u20137.","journal-title":"Hippokratia."},{"key":"246_CR131","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fpsyt.2017.00112","volume":"8","author":"D Vilaverde","year":"2017","unstructured":"Vilaverde D, Gon\u00e7alves J, Morgado P. Hoarding disorder: a case report. Front Psychiatry. 2017;8:112.","journal-title":"Front Psychiatry."},{"key":"246_CR132","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1017\/S1092852900008385","volume":"9","author":"A Kaplan","year":"2004","unstructured":"Kaplan A, Hollander E. Comorbidity in compulsive hoarding: a case report. CNS Spectr. 2004;9:71\u20133.","journal-title":"CNS Spectr"},{"key":"246_CR133","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/070674379604100511","volume":"41","author":"SA Chong","year":"1996","unstructured":"Chong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry. 1996;41:315\u20136.","journal-title":"Can J Psychiatry"},{"key":"246_CR134","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/JCP.0b013e318221b1ba","volume":"31","author":"MP White","year":"2011","unstructured":"White MP, Koran LM. Open-label trial of aripiprazole in the treatment of trichotillomania. J Clin Psychopharmacol. 2011;31:503\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"246_CR135","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1176\/appi.neuropsych.14090232","volume":"27","author":"AK Howard","year":"2015","unstructured":"Howard AK, Krishnamoorthy A, Leavitt BR, Raymond LA, Weissman CR. Treatment of Huntington disease and comorbid trichotillomania with aripiprazole. J Neuropsychiatry Clin Neurosci. 2015;27:e211\u20132.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"246_CR136","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2710.2009.01051.x","volume":"34","author":"O Virit","year":"2009","unstructured":"Virit O, Selek S, Savas HA, Koka\u00e7ya H. Improvement of restless legs syndrome and trichotillomania with aripiprazole. J Clin Pharm Ther. 2009;34:723\u20135.","journal-title":"J Clin Pharm Ther"},{"key":"246_CR137","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1002\/da.20395","volume":"25","author":"D Jefferys","year":"2008","unstructured":"Jefferys D, Burrows G. Reversal of trichotillomania with aripiprazole. Depress Anxiety. 2008;25:E37\u201340.","journal-title":"Depress Anxiety."},{"key":"246_CR138","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/WNF.0b013e318237b2c7","volume":"34","author":"N Yasui-Furukori","year":"2011","unstructured":"Yasui-Furukori N, Kaneko S. The efficacy of low-dose aripiprazole treatment for trichotillomania. Clin Neuropharmacol. 2011;34:258\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"246_CR139","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4088\/JCP.09m05114gre","volume":"71","author":"M Ameringen Van","year":"2010","unstructured":"Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010;71:1336\u201343.","journal-title":"J Clin Psychiatry"},{"key":"246_CR140","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4088\/JCP.v64n0110","volume":"64","author":"RS Stewart","year":"2003","unstructured":"Stewart RS, Nejtek VA. An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2003;64:49\u201352.","journal-title":"J Clin Psychiatry"},{"key":"246_CR141","first-page":"143","volume":"66","author":"M Gupta","year":"2000","unstructured":"Gupta M, Gupta AK. Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis. 2000;66:143\u20136.","journal-title":"Cutis"},{"key":"246_CR142","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1614.2005.01523.x","volume":"39","author":"RK Srivastava","year":"2005","unstructured":"Srivastava RK, Sharma S, Tiwari N, Saluja B. Olanzapine augmentation of fluoxetine in trichotillomania: two cases. Aust N Z J Psychiatry. 2005;39:112\u20133.","journal-title":"Aust N Z J Psychiatry"},{"key":"246_CR143","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1176\/ajp.155.9.1299a","volume":"155","author":"MN Potenza","year":"1998","unstructured":"Potenza MN, Wasylink S, Neill Epperson C, McDougle CJ. Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry. 1998;155:1299\u2013300.","journal-title":"Am J Psychiatry"},{"key":"246_CR144","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1176\/appi.ajp.158.11.1929-a","volume":"158","author":"AK Ashton","year":"2001","unstructured":"Ashton AK. Olanzapine augmentation for trichotillomania. Am J Psychiatry. 2001;158:1929\u201330.","journal-title":"Am J Psychiatry"},{"key":"246_CR145","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1590\/S1516-44462008000400019","volume":"30","author":"JAB Crescente Junior","year":"2008","unstructured":"Crescente Junior JAB, Guzman CS, Tavares H. Quetiapine for the treatment of trichotillomania. Rev Bras Psiquiatr. 2008;30:402.","journal-title":"Rev Bras Psiquiatr."},{"key":"246_CR146","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0033-3182(10)70728-3","volume":"51","author":"GC Jones","year":"2010","unstructured":"Jones GC, Coutinho K, Anjaria D, Hussain N, Dholakia R. Treatment of Recurrent Rapunzel Syndrome and Trichotillomania: case Report and Literature Review. Psychosomatics. 2010;51:443\u20136.","journal-title":"Psychosomatics."},{"key":"246_CR147","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1521\/psyc.65.3.261.20171","volume":"65","author":"HR Khouzam","year":"2002","unstructured":"Khouzam HR, Battista MA, Byers PE. An overview of trichotillomania and its response to treatment with quetiapine. Psychiatry. 2002;65:261\u201370.","journal-title":"Psychiatry."},{"key":"246_CR148","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/appi.psy.43.5.429","volume":"43","author":"V Senturk","year":"2002","unstructured":"Senturk V, Tanriverdi N. Resistant trichotillomania and risperidone. Psychosomatics. 2002;43:439\u201342.","journal-title":"Psychosomatics."},{"key":"246_CR149","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/070674370104600313","volume":"46","author":"A Gabriel","year":"2001","unstructured":"Gabriel A. A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Can J Psychiatry. 2001;46:285\u20136.","journal-title":"Can J Psychiatry"},{"key":"246_CR150","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jamda.2014.01.007","volume":"15","author":"R Oravecz","year":"2014","unstructured":"Oravecz R, \u0160tuhec M, Ko SM, Cohen LJ, Stein DJ, Simeon D, et al. Trichotillomania successfully treated with risperidone and naltrexone: a geriatric case report. J Am Med Dir Assoc Elsevier. 2014;15:301\u20132.","journal-title":"J Am Med Dir Assoc Elsevier"},{"key":"246_CR151","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/cap.1999.9.43","volume":"9","author":"CN Epperson","year":"1999","unstructured":"Epperson CN, Fasula D, Wasylink S, Price LH, McDougle CJ. Risperidone addition in serotonin reuptake inhibitor\u2013resistant trichotillomania: three cases. J Child Adolesc Psychopharmacol. 1999;9:43\u20139.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"246_CR152","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.4088\/JCP.v67n0821f","volume":"67","author":"WG Carter","year":"2006","unstructured":"Carter WG, Shillcutt SD. Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation. J Clin Psychiatry. 2006;67:1311.","journal-title":"J Clin Psychiatry"},{"key":"246_CR153","first-page":"29","volume":"11","author":"GA Turner","year":"2014","unstructured":"Turner GA, Sutton S, Sharma A. Augmentation of venlafaxine with aripiprazole in a case of treatment-resistant excoriation disorder. Innov Clin Neurosci. 2014;11:29\u201331.","journal-title":"Innov Clin Neurosci."},{"key":"246_CR154","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/070674370404901121","volume":"49","author":"RC Christensen","year":"2004","unstructured":"Christensen RC. Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking. Can J Psychiatry. 2004;49:788\u20139.","journal-title":"Can J Psychiatry"},{"key":"246_CR155","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-2133.2004.06151.x","volume":"151","author":"J Blanch","year":"2004","unstructured":"Blanch J, Grimalt F, Massana G, Navarro V. Efficacy of olanzapine in the treatment of psychogenic excoriation. Br J Dermatol. 2004;151:714\u20136.","journal-title":"Br J Dermatol"},{"key":"246_CR156","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00023210-200115050-00002","volume":"15","author":"LM Arnold","year":"2001","unstructured":"Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs. 2001;15:351\u20139.","journal-title":"CNS Drugs"},{"key":"246_CR157","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jclinepi.2010.09.003","volume":"64","author":"L Bax","year":"2011","unstructured":"Bax L, Moons KG. Beyond publication bias. J Clin Epidemiol. 2011;64:459\u201362.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 1","key":"246_CR158","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs. 2005;19(Suppl 1):1\u201392.","journal-title":"CNS Drugs"},{"key":"246_CR159","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00023210-199809030-00005","volume":"9","author":"MN Potenza","year":"1998","unstructured":"Potenza MN, McDougle CJ. Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs. 1998;9:213\u201332.","journal-title":"CNS Drugs"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0246-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0246-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0246-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:56:59Z","timestamp":1751828219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0246-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0246-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"31 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was used to assist with the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The following authors state there is no conflict of interest: Dongmi Kim, Nicole L. Ryba, Julie Kalabalik, and Ligia Westrich.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}